Asset Details
Do you wish to reserve the book?
CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology
Do you wish to request the book?
CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CSF evidence of pericyte damage in Alzheimer’s disease is associated with markers of blood-brain barrier dysfunction and disease pathology
2019
Overview
Background
We aimed to assess the relationship between levels of a cerebrospinal fluid (CSF) marker of pericyte damage, soluble platelet-derived growth factor receptor β (sPDGFRβ) and CSF markers of blood-brain barrier (BBB) integrity (CSF albumin and CSF/serum albumin ratio) and disease pathology (reduced CSF Aβ42 and elevated CSF total and phosphorylated tau) in Alzheimer’s disease (AD).
Methods
sPDGFRβ and albumin were measured by sandwich ELISA in ante-mortem CSF from 39 AD and 39 age-matched controls that were grouped according to their biomarker profile (i.e. AD cases t-tau > 400 pg/mL, p-tau > 60 pg/mL and Aβ42 < 550 pg/mL). sPDGFRβ was also measured in matched serum and CSF samples (
n
= 23) in a separate neurologically normal group for which the CSF/serum albumin ratio had been determined.
Results
CSF sPDGFRβ level was significantly increased in AD (
p
= 0.0038) and correlated positively with albumin (
r
= 0.45,
p
= 0.007), total tau (
r
= 0.50,
p
= 0.0017) and phosphorylated tau (
r
= 0.41,
p
= 0.013) in AD but not in controls. CSF sPDGFRβ did not correlate with Aβ42. Serum and CSF sPDGFRβ were positively correlated (
r
= 0.547,
p
= 0.0085) in the independent neurologically normal CSF/serum matched samples.
Conclusions
We provide further evidence of an association between pericyte injury and BBB breakdown in AD and novel evidence that a CSF marker of pericyte injury is related to the severity of AD pathology.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Albumins - cerebrospinal fluid
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - pathology
/ beta
/ Biomarkers - cerebrospinal fluid
/ Biomedical and Life Sciences
/ Blood-Brain Barrier - pathology
/ CSF
/ Dementia
/ Female
/ Humans
/ Male
/ PDGFRβ
/ Platelet-derived growth factor receptor beta
/ Platelet-derived growth factor receptor β
/ Receptor, Platelet-Derived Growth Factor beta - cerebrospinal fluid
